Design Therapeutics, Inc. - Common Stock — Quarterly Cash Flow (NASDAQ:DSGN) | MetaTrader

Open full chart

Financials

Overview Statement Statistics

Quarterly Annual

Total assets 237.47 M222.89 M211.77 M226.2 M230.44 M Total liabilities 9.56 M9.85 M12.05 M13.7 M12.39 M Total equity 227.92 M213.04 M199.72 M212.5 M218.05 M Total liabilities & shareholders' equities 237.47 M222.89 M211.77 M226.2 M230.44 M Total debt ————— Net debt —————

News

Design Therapeutics: FA Early Data And FDA Discussions Are Promising Catalysts

Are Medical Stocks Lagging Atea Pharmaceuticals (AVIR) This Year?

FDA Extends Review Time for AZN's Camizestrant Combo in Breast Cancer

AZN, Daiichi's Datroway Wins FDA Nod for Expanded Use in Breast Cancer

Design Therapeutics Stock Wobbles After Rare Genetic Disease Data - Design Therapeutics (NASDAQ:DSGN)

Design Therapeutics, Inc. (DSGN) Discusses Data from RESTORE-FA Trial of DT-216P2 for Friedreich Ataxia Transcript

This Biotech Leader Ran Up As Much As 18% — And Then Lost It All

Cramer: Design Therapeutics Is ‘Pure Spec,’ Buy This Health Care Stock - BillionToOne (NASDAQ:BLLN), Desi

Design Therapeutics, Inc. (DSGN) Is Up 6.92% in One Week: What You Should Know

Design Therapeutics, Inc. 2026 Q1 - Results - Earnings Call Presentation (NASDAQ:DSGN) 2026-04-30

Design Therapeutics, Inc. (DSGN) Q1 2026 Earnings Call Prepared Remarks Transcript

Jefferies initiates Design Therapeutics stock with buy on drug potential